home / stock / axim / axim news

AXIM News and Press, Axim Biotechnologies Inc From 10/04/22

Stock Information
Company Name: Axim Biotechnologies Inc
Stock Symbol: AXIM
Market: OTC
Website: aximbiotech.com
Menu
AXIM AXIM Quote AXIM Short AXIM News AXIM Articles AXIM Message Board
Get AXIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AXIM - Axim stock rises 11% on diagnostic tests order with partner Verséa

Axim Biotechnologies ( OTCQB:AXIM ) stock rose ~11% on Oct. 4 after the company said it received an initial order of 19K point-of-care diagnostic tests and 100 readers targeting ocular surface diseases through its exclusive commercialization partner Verséa Ophtha...
AXIM - AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has received an initi...

AXIM - AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics' Commercial Launch at AAO 2022

SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has start...

AXIM - AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa(TM) Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has signed an exclusive global commerci...
AXIM - AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has launche...

AXIM - AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20(TM) Podcast

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that its CEO John H...

AXIM - AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their publication in collaboration with researchers at Ari...
AXIM - AXIM Launches New Eye Care Website; Establishes Platform for Commercialization

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, today announced the launch of its ne...

AXIM - AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test - In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific te...

AXIM - AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it h...
Previous 10 Next 10